Sanofi backs fi­bro­sis biotech Agomab as it rais­es $89M Se­ries D

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

The Antwerp-based biotech said Fri­day that the French drug gi­ant and In­vus are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER